A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.
Also called NCT03969719
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose basic science
- Phase
- Phase 2
- Enrolled
- 164 participants
- Sponsor
- Registry
-
NCT03969719
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT03969719. Randomized; double masking; primary purpose basic science. Start 2019-07-18 (actual); primary completion 2021-03-02 (actual). Results posted on 2022-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
- Condition
- Non-alcoholic Steatohepatitis
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- PF-06835919
- Intervention (Drug)
- PF-06835919
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct03969719- Content hash
6c481c8e01a65827b9d995ee496fae10333006d2381ef993a867d1f2f76518db